Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

First Edition: June 20, 2014

First Edition: June 20, 2014

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

Anthrax, brucellosis and bovine TB fail to receive official recognition, say researchers

Anthrax, brucellosis and bovine TB fail to receive official recognition, say researchers

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm reports total revenue of $6.6 million for Q1 2014

Aradigm reports total revenue of $6.6 million for Q1 2014

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

Air, surface sampling techniques used by US government effective in fighting bioterrorism, says study

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Sandia develops credit-card-sized anthrax detection cartridge to small business makes

Sandia develops credit-card-sized anthrax detection cartridge to small business makes

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Study to understand role of bacterium in heart valve disease

Study to understand role of bacterium in heart valve disease

Researchers develop new method for rapid detection of anthrax

Researchers develop new method for rapid detection of anthrax

Researchers produce extremely accurate and detailed images of "toxic injections"

Researchers produce extremely accurate and detailed images of "toxic injections"

Researcher reveals the secrets of Francisella tularensis bacterium that causes tularemia

Researcher reveals the secrets of Francisella tularensis bacterium that causes tularemia

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Researchers discover unusually large bacteriophage that infects anthrax bacterium

Researchers discover unusually large bacteriophage that infects anthrax bacterium

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.